Scailyte™ is delighted to welcome investiere as an additional investor just before closing the pre-series A financing round.™
Today, Scailyte closed their pre-series A financing round with CHF 3.7 million led by Swisscom Ventures, joined by 4FO ventures, a private investor, Hemex and Investiere. This pre-series A financing round will allow Scailyte to develop faster their assays in the rapid-emerging single-cell data technology field. The raised capital will be used to further build upon Scailyte’s biomarker and IVD pipeline and for the development of the first clinical applications using single-cell biomarkers.
Scailyte is honored to have investiere among their renowned investor base. The additional financing increases the opportunities for Scailyte to develop in-vitro diagnostics using single-cell technologies and their proprietary single-cell data analysis platform ScaiVision™.
“We are continuously developing and utilizing our data analytics platform ScaiVision™ for biomarker discovery from single-cell data” says Peter Nestorov, CEO of Scailyte AG. “The current version covers all aspects of processing, handling and interpreting single-cell proteomics data (mass and flow cytometry), as well as a core functionality for analysing single-cell transcriptomics data. This allows us to accelerate biomedical discovery and enable the next generation of precision diagnostics. With the support of strong partners like Swisscom Ventures, 4FO and HEMEX, we will continue to grow in the fast-emerging single-cell analysis field, enabling various clinical applications of single-cell data “.
“Scailyte has a strong product pipeline. It includes candidates for biomarkers for Endometriosis and CTCL with a market potential of several hundred million Francs for each of these diagnostics. Furthermore, Scailyte enjoys strong support in the medical expert community” says Susanne Schorsch, Investment Manager at investiere.
investiere provides exclusive access to start-up investments to qualified private and institutional investors. investiere is one of the most active startup investors in Switzerland, backed by business angels as well as ZKB with more than 90 investments.
Scailyte AG was founded in Luzern, Switzerland in July 2017. Scailyte is an ETH Zurich spin-off and is supported by Innosuisse (Swiss Innovation Agency). The company has gained recognition by winning several national and international start-ups competitions and is the beneficiary of significant research grants. Scailyte has a multi-disciplinary team with expertise in Cell biology, Genetics, Artificial Intelligence, Software development, Finance, Marketing and Sales. Scailyte discovers ultrasensitive biomarkers and develops in-vitro diagnostics using single-cell technologies and their proprietary single-cell data analysis platform ScaiVision™. ScaiVision™ offers best-in-class analysis of complex single-cell data to enhance biomedical research, pharmaceutical discovery, and precision diagnostics. Besides developing its own in vitro diagnostic (IVD) applications, Scailyte also offers its biomarker discovery services to companies aiming to complement and enrich their analysis by adding the single-cell perspective.
The ScaiVision™ biomarker discovery platform delivers best-in-class performance for supervised pattern recognition analysis of single-cell data. The performance and clinically relevant application of the core deep learning algorithm of ScaiVision have been validated in several scientific papers and have resulted in patent-pending diagnostic applications. For more information visit www.scailyte.com
ScailyteTM and ScaiVisionTM are registered trademarks proprietary to Scailyte AG.
Recent News
Scailyte and Visterra Partner to Advance Autoimmune Disease Research
Scailyte AG, an AI-driven biomarker discovery company, and Visterra, Inc., a clinical-stage biopharm...
Recent News
Precision Medicine and The Future of Genomics Summit 2024
Scailyte at the Global Stage of Precision Medicine – PMFG 2024! We are proud to share that our CEO...
Recent News
Exploring Type 2 T Cell Immunity in Cancer—A Single-Cell Revolution
In this issue of ScaiDigest, we highlight two groundbreaking studies that expand the boundaries of i...
Recent News
Recent News
Pitch Nic 2024 at Novartis Campus
We’re thrilled to announce that our CEO, Peter Nestorov will join the innovative minds at Pitch Ni...
Recent News
Genomics for Health 2024
Don't miss Scailyte's CEO, Peter Nestorov, at the Genomics for Health 2024 event, bridging cutting-e...
Recent News
The Year of the AI Nobel
2024 is being hailed as the "Year of the AI Nobel," marking a milestone as artificial intelligence (...
Recent News
Life Science Industry Meets Data Science Symposium
Scailyte is thrilled to be part of the LIFE SCIENCE INDUSTRY MEETS DATA SCIENCE symposium organised ...
Recent News
Scailyte and Visterra Partner to Advance Autoimmune Disease Research
Scailyte AG, an AI-driven biomarker discovery company, and Visterra, Inc., a clinical-stage biopharm...
Precision Medicine and The Future of Genomics Summit 2024
Scailyte at the Global Stage of Precision Medicine – PMFG 2024! We are proud to share that our CEO...
Recent News
Exploring Type 2 T Cell Immunity in Cancer—A Single-Cell Revolution
In this issue of ScaiDigest, we highlight two groundbreaking studies that expand the boundaries of i...
Recent News
Pitch Nic 2024 at Novartis Campus
We’re thrilled to announce that our CEO, Peter Nestorov will join the innovative minds at Pitch Ni...
Genomics for Health 2024
Don't miss Scailyte's CEO, Peter Nestorov, at the Genomics for Health 2024 event, bridging cutting-e...
Recent News
The Year of the AI Nobel
2024 is being hailed as the "Year of the AI Nobel," marking a milestone as artificial intelligence (...
Life Science Industry Meets Data Science Symposium
Scailyte is thrilled to be part of the LIFE SCIENCE INDUSTRY MEETS DATA SCIENCE symposium organised ...